Engineering Strategies to Modulate the Gut Microbiome and Immune System.
Engineering Strategies to Modulate the Gut Microbiome and Immune System.
复制标题
DOI：
10.4049/jimmunol.2300480
复制
发表时间：
2024-01
影响因子：
4.4
通讯作者：
Kai Han;Jin Xu;Fang Xie;Julia Crowther;James J Moon
中科院分区：
文献类型：
--
作者：
Kai Han;Jin Xu;Fang Xie;Julia Crowther;James J Moon
肠道微生物群主要存在于结肠中，是一个复杂的生态系统，在宿主免疫系统中起着关键作用。肠道微生物群的生态失调与各种疾病有关，迫切需要开发靶向微生物组并恢复免疫功能的新疗法。这篇简短的综述讨论了新兴的治疗策略，重点是口服给药系统调节肠道微生物组。这些策略包括益生菌的基因工程、益生菌-生物材料杂合体、膳食纤维和微生物代谢物、抗菌肽、RNA和抗生素的口服递送系统。工程口服制剂在重塑肠道微生物组和影响临床前研究中的免疫反应方面表现出有希望的结果。通过利用这些方法，肠道微生物群和免疫系统之间的相互作用可以用于开发针对癌症，自身免疫性疾病和过敏症的新型疗法。
The gut microbiota, predominantly residing in the colon, is a complex ecosystem with a pivotal role in the host immune system. Dysbiosis of the gut microbiota has been associated with various diseases, and there is an urgent need to develop new therapeutics that target the microbiome and restore immune functions. This Brief Review discusses emerging therapeutic strategies that focus on oral delivery systems for modulating the gut microbiome. These strategies include genetic engineering of probiotics, probiotic-biomaterial hybrids, dietary fibers, and oral delivery systems for microbial metabolites, antimicrobial peptides, RNA, and antibiotics. Engineered oral formulations have demonstrated promising outcomes in reshaping the gut microbiome and influencing immune responses in preclinical studies. By leveraging these approaches, the interplay between the gut microbiota and the immune system can be harnessed for the development of novel therapeutics against cancer, autoimmune disorders, and allergies.